Poor sleep is associated with insulin resistance, increased hunger, and weight gain, which might reduce some benefits of GLP-1s [175]
Together, these actions are theorised to produce a more pronounced and sustained reduction in body weight compared with single or dual receptor agonists
Cravings for high-calorie foods decrease noticeably within the first few weeks
Consult with your doctor to discuss the benefits, risks, and costs of semaglutide and determine if it is right for you
Recommended starting dose: Discontinue other basal insulin and/or GLP-1 agonist before initiating Xultophy Patients nave to basal insulin or a GLP-1 agonist: starting dose is 10 units once daily Patients currently on basal insulin or a GLP-1 agonist: starting dose is 16 units once daily Maintenance: titrate dose up or down by 2 units once or twice weekly, depending on blood sugar goals Missed doses: resume dosing at the next scheduled dose
This is important because the plan may require provincial coverage to be pursued first and needs documentation to assess supplemental coverage
